Product Code: GVR-4-68038-132-0
Hyaluronidase Market Growth & Trends:
The global hyaluronidase market size is expected to reach USD 1,734.6 million by 2030 growing at a CAGR of 8.4% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The significance of minimally invasive cosmetic procedures has increased considerably over the years and various demographic research studies have been conducted to evaluate the adoption pattern of cosmetic treatments across the globe, especially in developed countries.
Hyaluronic acid fillers form the most important component of minimally invasive aesthetic procedures carried out across the globe. Since hyaluronidase is mostly preferred while conducting these procedures, a growing number of minimally invasive aesthetic surgeries are expected to positively impact market growth. Dermal fillers have significant applications in minimally invasive facial aesthetic procedures, which has also led to an increase in the number of reported complications.
Clinicians are required to be entirely aware of the symptoms associated with hyaluronic acid injection complications in order to treat them effectively. It is crucial to establish effective protocols of action suitable for emergencies wherein the desired agents are readily available at the site of surgery or treatment. This aids in controlling the adverse impact of hyaluronic acid filler injections.
Hyaluronidase Market Report Highlights:
- Animal derived hyaluronidase segment held the largest revenue share of 67.0% in 2022 and are anticipated to maintain this trend throughout the forecast period
- Synthetic hyaluronidase segment is anticipated to register the fastest CAGR of 9.4% over the forecast period
- The Dermatology segment held the largest revenue share of approximately 44.6% in 2022
- The chemotherapy segment is estimated to register the fastest CAGR of 10.5% over the forecast period.
- North America dominated the market in 2022 with the largest revenue share of 38.0% due to the high penetration of novel cosmetic treatments. In addition, dermatologists in this region are developing new non-surgical cosmetic procedures and hyaluronidase-based injectables which are among the highly recommended injectable dermal fillers
- Asia Pacific is projected to witness the fastest growth owing to the numerous untapped growth opportunities in hyaluronidase-based treatments
- A robust network of local manufacturers has significantly contributed to the revenue generated from this region
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Type
- 1.1.2. Application
- 1.1.3. Regional scope
- 1.1.4. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Type outlook
- 2.2.2. Application outlook
- 2.2.3. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Hyaluronidase Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Market Dynamics
- 3.3.1. Market Driver Analysis
- 3.3.2. Market Restraint Analysis
- 3.4. Hyaluronidase Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's
- 3.4.1.1. Supplier power
- 3.4.1.2. Buyer power
- 3.4.1.3. Substitution threat
- 3.4.1.4. Threat of new entrant
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Technological landscape
- 3.4.2.3. Economic Landscape
Chapter 4. Hyaluronidase: Type Estimates & Trend Analysis
- 4.1. Hyaluronidase Market: Key Takeaways
- 4.2. Hyaluronidase Market: Movement & Market Share Analysis, 2022 & 2030
- 4.3. Animal-derived hyaluronidase
- 4.3.1. Animal-derived hyaluronidase market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4. Synthetic hyaluronidase
- 4.4.1. Synthetic hyaluronidase market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Hyaluronidase: Application Estimates & Trend Analysis
- 5.1. Hyaluronidase Market: Key Takeaways
- 5.2. Hyaluronidase Market: Movement & Market Share Analysis, 2022 & 2030
- 5.3. Dermatology
- 5.3.1. Dermatology market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4. Chemotherapy
- 5.4.1. Chemotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5. Ophthalmology
- 5.5.1. Ophthalmology market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.6. Plastic Surgery
- 5.6.1. Plastic Surgery market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.7. Others
- 5.7.1. Other market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Hyaluronidase Market: Regional Estimates & Trend Analysis
- 6.1. Regional Outlook
- 6.2. Hyaluronidase Market by Region: Key Takeaways
- 6.3. North America
- 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.3.2. U.S.
- 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.3.3. Canada
- 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4. Europe
- 6.4.1. UK
- 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.2. Germany
- 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.3. France
- 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.4. Italy
- 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.5. Spain
- 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.6. Sweden
- 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.7. Norway
- 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.8. Denmark
- 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5. Asia Pacific
- 6.5.1. Japan
- 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.2. China
- 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.3. India
- 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.4. Australia
- 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.5. Thailand
- 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.6. South Korea
- 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.6. Latin America
- 6.6.1. Brazil
- 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.6.2. Mexico
- 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.6.3. Argentina
- 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.7. MEA
- 6.7.1. Saudi Arabia
- 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.7.2. South Africa
- 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.7.3. UAE
- 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.7.4. Kuwait
- 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
- 7.1. Recent Developments & Impact Analysis, By Key Market Participants
- 7.2. Market Participant Categorization
- 7.2.1. Amphastar Pharmaceuticals, Inc.
- 7.2.1.1. Company overview
- 7.2.1.2. Financial performance
- 7.2.1.3. Product benchmarking
- 7.2.1.4. Strategic initiatives
- 7.2.2. PrimaPharma, Inc.
- 7.2.2.1. Company overview
- 7.2.2.2. Financial performance
- 7.2.2.3. Product benchmarking
- 7.2.2.4. Strategic initiatives
- 7.2.3. Halozyme, Inc.
- 7.2.3.1. Company overview
- 7.2.3.2. Financial performance
- 7.2.3.3. Product benchmarking
- 7.2.3.4. Strategic initiatives
- 7.2.4. Bausch & Lomb Incorporated
- 7.2.4.1. Company overview
- 7.2.4.2. Financial performance
- 7.2.4.3. Product benchmarking
- 7.2.4.4. Strategic initiatives
- 7.2.5. The Cooper Companies Inc.
- 7.2.5.1. Company overview
- 7.2.5.2. Financial performance
- 7.2.5.3. Product benchmarking
- 7.2.5.4. Strategic initiatives
- 7.2.6. Sun Pharmaceutical Industries Ltd.
- 7.2.6.1. Company overview
- 7.2.6.2. Financial performance
- 7.2.6.3. Product benchmarking
- 7.2.6.4. Strategic initiatives
- 7.2.7. STEMCELL Technologies Inc.
- 7.2.7.1. Company overview
- 7.2.7.2. Financial performance
- 7.2.7.3. Product benchmarking
- 7.2.7.4. Strategic initiatives
- 7.2.8. Shreya Life Sciences Pvt. Ltd.
- 7.2.8.1. Company overview
- 7.2.8.2. Financial performance
- 7.2.8.3. Product benchmarking
- 7.2.8.4. Strategic initiatives